[Pathogenetic therapy of metabolic syndrome at the stage of visceral lesions]

Area of Science:

• Hepatology
• Metabolic Syndrome
• Oxidative Stress

Background:

• Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves insulin resistance and oxidative stress.
• Targeting oxidative stress (the second phase of NAFLD pathogenesis) offers a promising therapeutic strategy.
• Restoring mitochondrial and cellular functions presents an alternative treatment approach.

Purpose of the Study:

• To evaluate the clinical efficacy of remaxol, a succinic acid-based metabolic agent, in the pathogenetic therapy of non-alcoholic steatohepatitis (NACH).
• To assess remaxol's impact on liver function, lipid metabolism, and renal function in patients with NACH and metabolic syndrome.

Main Methods:

• Original clinical study involving patients with NACH and metabolic syndrome.
• Assessment of liver function through ultrasound to evaluate cytolysis, cholestasis, hepatomegaly, and steatosis.
• Monitoring of lipid metabolism parameters (cholesterol, triglycerides, atherogenic index) and renal function (glomerular filtration rate, creatinine).

Main Results:

• Remaxol improved liver function by reducing cytolysis, cholestasis, hepatomegaly, and steatosis.
• Treatment with remaxol led to improvements in lipid metabolism, lowering cholesterol, triglyceridemia, and the atherogenic index.
• Remaxol demonstrated nephroprotective effects in patients with diabetic nephropathy, improving glomerular filtration rate and reducing blood creatinine.

Conclusions:

• Remaxol is an effective metabolic hepatoprotector for NACH, offering advantages over traditional therapies.
• Succinic acid-based medications with antihypoxic properties show promise in managing NACH.
• Remaxol exhibits a dual benefit, improving both liver and kidney function in relevant patient populations.